Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TCC

Complement Factor D inhibited with JH4

Summary for 5TCC
Entry DOI10.2210/pdb5tcc/pdb
Related5TCA
DescriptorComplement factor D, (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide (2 entities in total)
Functional Keywordsserine protease, inhibitor, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains7
Total formula weight175088.54
Authors
Stuckey, J.A. (deposition date: 2016-09-14, release date: 2016-10-19, Last modification date: 2024-10-30)
Primary citationYang, C.Y.,Phillips, J.G.,Stuckey, J.A.,Bai, L.,Sun, H.,Delproposto, J.,Brown, W.C.,Chinnaswamy, K.
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.
ACS Med Chem Lett, 7:1092-1096, 2016
Cited by
PubMed Abstract: Aberrant activation of the complement system is associated with diseases, including paroxysmal nocturnal hemoglobinuria and age-related macular degeneration. Complement factor D is the rate-limiting enzyme for activating the alternative pathway in the complement system. Recent development led to a class of potent amide containing pyrrolidine derived factor D inhibitors. Here, we used biochemical enzymatic and biolayer interferometry assays to demonstrate that the amide group improves the inhibitor potency by more than 80-fold. Our crystal structures revealed buried hydrogen bond interactions are important. Molecular orbital analysis from quantum chemistry calculations dissects the chemical groups participating in these interactions. Free energy calculation supports the differential contributions of the amide group to the binding affinities of these inhibitors. Cell-based hemolysis assay confirmed these compounds inhibit factor D mediated complement activation via the alternative pathway. Our study highlights the important interactions contributing to the high potency of factor D inhibitors reported recently.
PubMed: 27994744
DOI: 10.1021/acsmedchemlett.6b00299
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.37 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon